Abstract
OBJECTIVES: The incidence of chikungunya and dengue is increasing worldwide. Vaccines are now available against these two arboviral diseases. METHODS: We evaluated the acceptability of live chikungunya and dengue vaccines (VLA1553 and TAK-003) among users of Martinique's travel clinics from January to April 2025. We asked whether they would want these vaccines for travel to areas with exposure risk and/or for their home territory. RESULTS: While planning travel, 41% of respondents expressed interest in the chikungunya vaccine, and 55% were interested in the dengue vaccine. For the Martinique territory, 55% were willing to receive the chikungunya vaccine, and 58% were willing to receive the dengue vaccine. CONCLUSIONS: In both contexts (travel and home territory), acceptability was higher for dengue than for chikungunya vaccination. Acceptability for both vaccines was also higher for the home territory than for travel to areas with exposure risk. Few data are available on chikungunya vaccine acceptability. We found similar acceptability for this vaccine in Martinique as reported in the United States Virgin Islands (56%), an overseas territory of the United States in the Caribbean, and in La Réunion, another French overseas territory in the Indian Ocean (60.5% in the hypothetical full-reimbursement scenario).